Diagnosis of DLBCL
Surgical excisional biopsy is the gold standard for diagnosing DLBCL and must be performed at a reference hematopathology laboratory with comprehensive morphological and molecular capabilities. 1
Tissue Acquisition
Biopsy Method
- Surgical excisional biopsy is mandatory as the optimal diagnostic approach, allowing complete assessment of nodal architecture and providing adequate tissue for all necessary studies 1
- Send the specimen unfixed to the laboratory to enable flow cytometry and extraction of high-quality DNA/RNA 1
- Needle-core or endoscopic biopsies should only be used when surgical biopsy poses excessive risk or is impractical 1
- Fine-needle aspirate alone is contraindicated for DLBCL diagnosis and should never be the sole diagnostic method 1
Critical pitfall: Using FNA alone will miss architectural patterns and provide insufficient material for comprehensive immunophenotyping and molecular studies, potentially leading to misdiagnosis or incomplete characterization.
Required Laboratory Workup
Immunophenotypic Confirmation
All morphological diagnoses must be confirmed by immunophenotypic investigations using immunohistochemistry (IHC), flow cytometry, or both 1. The immunohistochemical panel should include:
- CD20, CD79a (confirm B-cell lineage)
- BCL6, CD10, MYC, BCL2, Ki67 (prognostic markers and cell-of-origin determination)
- IRF4, CyclinD1, CD5, CD23 (exclude alternative diagnoses)
- EBER-1 staining (identify EBV-positive DLBCL in elderly) 1
This comprehensive panel distinguishes DLBCL from critical mimics including Burkitt lymphoma, plasmablastic lymphoma, blastic mantle cell lymphoma, and Hodgkin lymphoma 1.
Molecular Studies
- PCR-based B-cell monoclonality testing should be performed when diagnostic confidence is reduced (small biopsy, normal phenotype by IHC) 1
- FISH for MYC and BCL2 rearrangements is recommended in all newly diagnosed patients treated with curative intent to identify double-hit/triple-hit lymphomas 1
Important nuance: While cell-of-origin (germinal center vs. activated B-cell) determined by gene expression profiling has prognostic significance, IHC-based determination shows contradictory results and should not guide clinical decisions 1.
Staging Workup
Clinical Assessment
- Physical examination with performance status and B symptoms documentation 1
- Complete blood count and comprehensive metabolic panel including LDH and uric acid 1
- Screening for HIV, HBV, and HCV (mandatory) 1
- Protein electrophoresis 1
- Cardiac function assessment (LVEF) before anthracycline-based therapy 1
Imaging
FDG-PET/CT is the gold standard for staging DLBCL and is essential as baseline for subsequent response assessment 1, 2. If contrast-enhanced CT was not performed before PET/CT, add diagnostic high-dose contrast CT when needed for accurate nodal measurement or vessel assessment 1.
Bone marrow biopsy may be omitted when PET/CT demonstrates bone/marrow involvement indicating advanced-stage disease, but is appropriate with negative PET when results would alter prognosis or treatment (especially if abbreviated chemotherapy cycles are considered) 1.
CNS Risk Assessment
- MRI is the imaging modality of choice for suspected CNS involvement 1
- Diagnostic lumbar puncture should be considered in high-risk patients (specific high-risk features include testicular involvement, kidney involvement, breast involvement, or multiple extranodal sites) 1
Risk Stratification
- Stage according to Ann Arbor classification 1
- Calculate International Prognostic Index (IPI) and age-adjusted IPI for prognostic purposes 1
Critical consideration: The diagnostic workup directly impacts mortality and quality of life by ensuring accurate subtype identification (particularly double-hit lymphomas), appropriate risk stratification, and detection of CNS involvement—all of which fundamentally alter treatment approach and outcomes.